Oxidized low‐density lipoproteins as a novel risk factor and therapeutic target for ACM

Oxidized low‐density lipoproteins as a novel risk factor and therapeutic target for ACM

Arrhythmogenic cardiomyopathy (ACM) is an inherited heart disease involving arrhythmia in young adults accompanied by structural changes at later stages. In this issue of EMBO Molecular Medicine, Sommariva et al (2021) identified a positive correlation between circulating levels of oxidized low‐dens...

Full description

Bibliographic Details
Main Authors: Hoyee Tsui, Su Ji Han, Eva van Rooij
Format: Article
Language:English
Published: Wiley 2021-09-01
Series:EMBO Molecular Medicine
Online Access:https://doi.org/10.15252/emmm.202114789
id doaj-66a89c8e42df4cb297bfb5c7f7c9fec1
record_format Article
spelling doaj-66a89c8e42df4cb297bfb5c7f7c9fec12021-09-07T07:49:47ZengWileyEMBO Molecular Medicine1757-46761757-46842021-09-01139n/an/a10.15252/emmm.202114789Oxidized low‐density lipoproteins as a novel risk factor and therapeutic target for ACMHoyee Tsui0Su Ji Han1Eva van Rooij2Hubrecht Institute KNAW and University Medical Center Utrecht Utrecht The NetherlandsHubrecht Institute KNAW and University Medical Center Utrecht Utrecht The NetherlandsHubrecht Institute KNAW and University Medical Center Utrecht Utrecht The NetherlandsArrhythmogenic cardiomyopathy (ACM) is an inherited heart disease involving arrhythmia in young adults accompanied by structural changes at later stages. In this issue of EMBO Molecular Medicine, Sommariva et al (2021) identified a positive correlation between circulating levels of oxidized low‐density lipoproteins (oxLDL) and ACM disease penetrance, which contributes to fibro‐fatty cardiac remodeling via the oxLDL/CD36/PPARγ axis. These data identify oxidized low‐density lipoproteins as a risk factor for ACM and uncover a novel therapeutic intervention option to block disease pathogenesis.https://doi.org/10.15252/emmm.202114789
collection DOAJ
language English
format Article
sources DOAJ
author Hoyee Tsui
Su Ji Han
Eva van Rooij
spellingShingle Hoyee Tsui
Su Ji Han
Eva van Rooij
Oxidized low‐density lipoproteins as a novel risk factor and therapeutic target for ACM
EMBO Molecular Medicine
author_facet Hoyee Tsui
Su Ji Han
Eva van Rooij
author_sort Hoyee Tsui
title Oxidized low‐density lipoproteins as a novel risk factor and therapeutic target for ACM
title_short Oxidized low‐density lipoproteins as a novel risk factor and therapeutic target for ACM
title_full Oxidized low‐density lipoproteins as a novel risk factor and therapeutic target for ACM
title_fullStr Oxidized low‐density lipoproteins as a novel risk factor and therapeutic target for ACM
title_full_unstemmed Oxidized low‐density lipoproteins as a novel risk factor and therapeutic target for ACM
title_sort oxidized low‐density lipoproteins as a novel risk factor and therapeutic target for acm
publisher Wiley
series EMBO Molecular Medicine
issn 1757-4676
1757-4684
publishDate 2021-09-01
description Arrhythmogenic cardiomyopathy (ACM) is an inherited heart disease involving arrhythmia in young adults accompanied by structural changes at later stages. In this issue of EMBO Molecular Medicine, Sommariva et al (2021) identified a positive correlation between circulating levels of oxidized low‐density lipoproteins (oxLDL) and ACM disease penetrance, which contributes to fibro‐fatty cardiac remodeling via the oxLDL/CD36/PPARγ axis. These data identify oxidized low‐density lipoproteins as a risk factor for ACM and uncover a novel therapeutic intervention option to block disease pathogenesis.
url https://doi.org/10.15252/emmm.202114789
work_keys_str_mv AT hoyeetsui oxidizedlowdensitylipoproteinsasanovelriskfactorandtherapeutictargetforacm
AT sujihan oxidizedlowdensitylipoproteinsasanovelriskfactorandtherapeutictargetforacm
AT evavanrooij oxidizedlowdensitylipoproteinsasanovelriskfactorandtherapeutictargetforacm
_version_ 1717764345375490048

Similar Items